A scalable, virtual weight management program tailored for adults with type 2 diabetes: effects on glycemic control.

"Competing interests JWA: Grants NIH NIDDK and NIMHD, NSF, and USDA. JGL: Grants NIH NIDDK. FLG: Consultant: Ed Med Resources, NovMeta Pharma, GNC, Basic Research, Scientific Advisory Board: Altimune, Pfizer, Nutraceutical Corporation, Stock/stock options: UR Labs, Plensat, Ketogenic Health Systems, Slim Health Nutrition, Energesis, Rejuvenate Bio, Patents: Melior Discoveries (Tolimidone/menthol). Grants: NovMeta Pharma. GDF: Employee and Shareholder at WW. MIC: Grants: National Institute of Health NHLBI and NIDDK. Stock/Stock Options: WW International, Inc. Employee at WW International, Inc. The authors declare no other competing interests."

"Funding This work was funded by WW International, Inc."

"This single-arm, three-site trial included Pennington Biomedical Research Center in Baton Rouge, LA, University of Florida in Gainesville, FL, and Virginia Commonwealth University in Richmond, VA. All participants were given verbal and written explanations about the study, provided written informed consent, and received incentives for data collection visits ($50 at 0 and 12 weeks, $125 at 24 weeks). Participants were recruited in cohorts, ranging from 7 to 31 participants (mean n = 17), between April–June 2021. The study was approved by the Institutional Review Boards at all three sites and registered at ClinicalTrials.gov (NCT04804774)."